46888 ther N H carmengabriela The shares of German pharmaceutical firm BioNTech (NASDAQ:BNTX) have rallied about 13% in the last two days. The gains could have been sparked by the success of Summit Therapeutics' (SMMT) bispecific antibody, ivonescimab, in a Phase III trial involving previously untreated patients with locally advanced or metastatic positive PD-L1 non-small cell lung cancer (NSCLC). Since BioNTech licensed a similar antibody last November from China-based biotech firm Biotheus, some investors ...

MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology ("ESMO") Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech's clinical pipeline, including mRNAbased cancer vaccines, next-generation immunomodulators and targeted therapy approaches. "We believ ...

Delhi, Aug. 25, 2024 (GLOBE NEWSWIRE) -- A significant breakthrough in cancer treatment was achieved with the initiation of the first mRNA lung cancer vaccine trials globally. This innovative project, featuring BioNTech's BNT116, heralds the dawn of a transformative period in cancer therapy domain, with the potential to fundamentally change our strategies for cancer therapy. BNT116 is specifically engineered to combat nonsmall cell lung cancer (NSCLC) and signifies a major progression in the field of person ...

A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease. Janusz Racz, 67, had six syringes of the jab, each containing genetic material for a different part of the tumour, to train five billion cells in his immune system to go on the attack. The vaccine, codenamed BNT116, is made by BioNTech using the same mRNA technology that underpinned its highly effective COVID jab. Doctors say it is far more precisely targeted than chemotherapy so sh ...

Pyrosky/iStock via Getty Images Investment Overview BioNTech SE (NASDAQ:BNTX), the Mainz, Germany-based Pharma company that partnered with Pfizer (PFE) in creating the most successful vaccine of the COVID19 era, Comirnaty, using a pioneering messenger-RNA ("MRNA") approach, reported its Q2 2024 earnings yesterday. I last covered BioNTech for Seeking Alpha in June, summarizing its recent fortunes as follows: BioNTech launched its initial public offering ("IPO") back in October 2019, raising $150m at $15 per ...

BioNTech SE (NASDAQ:BNTX) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Victoria Meissner - Vice President, Strategy & Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Yaron Werber - TD Cowen Tazeen Ahmad - Bank of America Securities Etzer Darout - BMO Capital Ma ...

| --- | --- | --- | --- | --- | |--------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | nd | | | | | | 2 Quarter 2024 | | | | | | | | | | | | Financial Results & Corporate Update | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | August 5, 2024 | | | | | | | | | | | | ...

Exhibit 99.1 BIONTECH BioNTech SE Quarterly Report of BioNTech SE for the three and six months ended June 30, 2024 A C T I N G T O G E T H E R C R E A T I N G S Y N E R G I E S A C T I N G T O G E T H E R — C R E A T I N G S Y N E R G I E S Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not pa ...

Announced positive data from multiple mRNA cancer vaccine clinical trials, including topline results from the ongoing Phase 2 evaluating FixVac candidate BNT111 Launched updated variant-adapted COVID-19 vaccine in the European Union ("EU"), received approval in the United Kingdom and initiated rolling supplemental Biologics Licensing Application ("sBLA") with the United States Food and Drug Administration ("U.S. FDA") Reiterates guidance for total revenues in the range of €2.5-3.1 billion Reports second qua ...

Announced positive data from multiple mRNA cancer vaccine clinical trials, including topline results from the ongoing Phase 2 evaluating FixVac candidate BNT111 Launched updated variant-adapted COVID-19 vaccine in the European Union ("EU"), received approval in the United Kingdom and initiated rolling supplemental Biologics Licensing Application ("sBLA") with the United States Food and Drug Administration ("U.S. FDA") Reiterates guidance for total revenues in the range of €2.5-3.1 billion Reports second qua ...